Journal article
In a Subgroup of High-Risk Asians, Telmisartan Was Non-Inferior to Ramipril and Better Tolerated in the Prevention of Cardiovascular Events
Abstract
BACKGROUND AND OBJECTIVES: Results of the recently published ONTARGET study (The Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial) showed that telmisartan (80 mg/day) was non-inferior to ramipril (10 mg/day) in reducing cardiovascular events. Clinicians in Asia doubt tolerability of these doses for their patients. We therefore analyzed data from this study and a parallel study TRANSCEND (Telmisartan Randomized …
Authors
Dans AL; Teo K; Gao P; Chen J-H; Jae-Hyung K; Yusoff K; Chaithiraphan S; Zhu J; Lisheng L; Yusuf S
Journal
PLOS ONE, Vol. 5, No. 12,
Publisher
Public Library of Science (PLoS)
DOI
10.1371/journal.pone.0013694
ISSN
1932-6203